Clinical effects of treatment of gonadotropin releasing hormone agonist combined with oral contraceptive on endometriosis
10.3760/cma.j.issn.1008-6315.2014.04.005
- VernacularTitle:促性腺激素释放激素激动剂与口服避孕药联合治疗子宫内膜异位症的效果观察
- Author:
Linghua LI
;
Xiuli SHI
- Publication Type:Journal Article
- Keywords:
Endometriosis;
Gonadotropin-releasing hormone agonist;
Contraceptives
- From:
Clinical Medicine of China
2014;30(4):350-352
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the treatment effect of gonadotropin releasing hormone agonist and oral contraceptive on endometriosis diseases.Methods One hundred and eighty-six cases with endometriosis who were hospitalized in Traditional Chinese Medicine Hospital of Fangshan District of Beijing from Jan.2012 to Dec.2012,were randomly divided into control group (93 cases) and observation group (93 cases).Patients in control group were given Marvelon by oral from the first day of menstruation after operation to 6 months,1 tablet/day,and patients in observation group were given Marvelon combined with Zoladex after laparoscopic conservative treatment (3.6 ml subcutaneous injected Zoladex from the first week after operation,4 weeks/time,3 times).The total subjective symptom scores,efficacy rate,Pregnancy rate and adverse reaction were calculated and recorded.Results Subjective symptom score of observation group was (0.91 ± 0.32),significantly lower than that of the control group (1.64 ± 0.74 ; t =8.73,P ＜ 0.01).The efficiency rate in observation group were 95.70％ (89/93) was significantly higher than that in control group(82.80％ (77/93) ;t =4.328,P ＜0.05).Adverse reactions rate and reoccurrence in observation group were 4.30％ (4/93) and 3.23％ (3/93),lower than that of the control group(16.13％ (15/93) and 10.75％ (10/93) ; x2 =4.854,5.168 ; P ＜ 0.05).After treatment,the pregnancy rate in infertile patients of observation group the was 85.71％ (12/14),significantly higher than that of the control group (61.54％ (8/13),x2 =3.987,P ＜ 0.05).Conclusion Gonadotropinreleasing hormone agonist combined contraceptive is worthy of recommendation due to alleviating clinical symptoms,reducing adverse reactions occur,the relapse rate and improving the chances of conceiving infertility patients.
